• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Prestigious Residential Treatment Provider, Beau Monde Programs to Initially Offer PROMETA at Flagship Newport Beach Location; Hythiam Expands Access to PROMETA(TM) in Orange County, California

Posted on: Tuesday, 22 August 2006, 09:01 CDT

Hythiam, Inc. (NASDAQ:HYTM), the healthcare services management company that licenses the PROMETA(TM) treatment protocols designed to treat alcohol, methamphetamine, and cocaine dependence, announced today that it has entered into a licensing agreement with Beau Monde Programs to initially offer its PROMETA protocols at its flagship Newport Beach location, an ultra-exclusive residential treatment facility. Beau Monde Programs also operates private treatment centers in Laguna Beach and Hollywood catering to celebrities, pro athletes, executives, physicians and other high profile clientele.

Commenting on the relationship, Founder/CEO of Beau Monde, Heidi E. Kunzli, said, "We have a long waiting list for treatment at our facilities since we are very exclusive and private, catering to high net-worth individuals with extremely specialized needs. Our programming philosophy at Beau Monde is one of innovation and of offering the latest and most cutting-edge advances in treatment and recovery. As is widely understood across the board, there is no cure for addiction. It is agreed among the wide majority of healthcare professionals that 'addiction' is a complex condition involving biological, physiological, psychological, social, emotional and spiritual factors. In accord with this 'holistic' way of looking at the challenge of treating 'addiction,' Beau Monde's treatment team focuses on the entire matrix of factors affecting an individual's health and well-being."

Kunzli continued, "We are excited to offer the PROMETA protocols to our clients. In our belief, the combination of the PROMETA treatment coupled with Beau Monde's individualized programming ensures a powerful and profound change experience for our clients seeking relief from addiction. The PROMETA protocols fit beautifully into our unique, one-on-one program where we treat each person using a science-based, holistic, truly person-centered approach."

Beau Monde Programs use motivational enhancement therapy which is one of the approaches, based on studies, endorsed by the National Institute on Drug Abuse (NIDA).

"Orange County is a key geographic region to Hythiam and the addition of Beau Monde Programs as our newest licensee will help provide increased patient access for PROMETA in the Southern California region," said Terren Peizer, Hythiam's Chairman and CEO. "Beau Monde represents an approach to addiction treatment that emphasizes highly individualized treatment and the use of the best available treatments in order to affect better outcomes.

Unlike traditional high-end residential treatment facilities where high profile individuals are treated the same as regular patients, Beau Monde Programs takes into account the unique needs of these individuals and tailors a treatment program to those needs.

About Beau Monde Programs

The Beau Monde Transformational Recovery(TM) approach is based on the belief that recovery from burnout, substance abuse, addictions, chronic pain, compulsive behaviors, stress and other life challenges should be looked at from a whole person, multi-dimensional perspective. It stems from motivational, cognitive and humanistic psychology which emphasize that each individual has tremendous freedom in directing his or her future, a large capacity for personal growth, a considerable amount of intrinsic worth, and enormous potential for self-fulfillment. This view looks at individuals as being internally directed and motivated to fulfill their human potential. A person's concept of the "self" influences behavior and is related to emotional state, well-being and judgment in the individual. In accordance with this belief, the Beau Monde Transformational Recovery(TM) approach looks at "relapse" as no longer an issue in the "recovering" individual once he or she can identify, develop and live life in accordance with their true, authentic self.

About PROMETA(TM)

Hythiam's PROMETA(TM) treatment protocols are designed for use by healthcare providers seeking to treat individuals diagnosed with dependencies to alcohol, cocaine or methamphetamine, as well as combinations of these drugs. The PROMETA treatment protocols comprise nutritional supplements, FDA-approved oral and IV medications used off-label and separately administered in a unique dosing algorithm, as well as psychosocial or other recovery-oriented therapy chosen by the patient and his or her treatment provider. As a result, PROMETA represents an innovative approach to managing alcohol, cocaine, or methamphetamine dependence that is designed to address physiological, nutritional, and psychosocial aspects of the disease, and is thereby intended to offer patients an opportunity to achieve sustained recovery. For further information, please click on www.prometainfo.com.

About Hythiam, Inc.

Hythiam(R) is a healthcare services management company focused on delivering solutions for those suffering from alcoholism and other substance dependencies. Hythiam researches, develops, licenses and commercializes innovative physiological, nutritional, and behavioral treatment protocols that seek to address substance dependence. Additionally, Hythiam provides proprietary administrative services to assist physicians and facilities with staff education, marketing and outreach support, and outcomes tracking for data analysis. For further information, please click on www.hythiam.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history and lack of statistically significant formal research studies, the risk that treatment protocols might not be effective, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the healthcare industry; and additional risks factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at http://www.sec.gov.

Source: Business Wire

More News in this Category